Featured Research

from universities, journals, and other organizations

Genetic regulator identified as possible treatment target in melanoma

Date:
April 3, 2014
Source:
Rutgers Cancer Institute of New Jersey
Summary:
The RUNX2 protein, which regulates the transcription of genetic messages responsible for the different functions of cells, may play a role in melanoma cell growth and spread, and could serve as a therapeutic target for the disease, research shows. Abnormal and uncontrolled production of this class of proteins, known as transcription factors, allow for cells to bypass growth control mechanisms and to develop characteristics necessary for invading surrounding tissues. Some transcription factors already have been identified as playing a role in melanoma development. These discoveries come into a favorable context of new drugs against transcription factors being tested in clinical trials.

Research from Rutgers Cancer Institute of New Jersey shows that the RUNX2 protein, which regulates the transcription of genetic messages responsible for the different functions of cells, may play a role in melanoma cell growth and spread and could serve as a therapeutic target for the disease.

Related Articles


Abnormal and uncontrolled production of this class of proteins, known as transcription factors, allow for cells to bypass growth control mechanisms and to develop characteristics necessary for invading surrounding tissues. Some transcription factors already have been identified as playing a role in melanoma development. These discoveries come into a favorable context of new drugs against transcription factors being tested in clinical trials. In the study, published in the current online edition of Cancer Letters, senior author Karine Cohen-Solal, PhD, and colleagues show for the first time that the RUNX2 transcription factor could also serve as a possible treatment target for melanoma.

This latest research shows deviant messaging translated through RUNX2 may result in melanoma growth, migration and invasion. In order to further understand the impact of such abnormal messaging, investigators artificially reduced the amount of RUNX2 in melanoma cells through a genetic approach. As a result, reduced abilities for cell growth, migration and invasion were found.

"Successful efforts to render transcription factors 'drugable' by interfering with different aspects of their transcriptional activity make this class of proteins attractive targets for therapy," says Dr. Cohen-Solal, a researcher at the Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. "Exploring the role of RUNX2 in the development of melanoma is likely to reveal new mechanisms driving melanoma progression and identify a target for novel anti-melanoma agents, thereby opening new avenues for the treatment of this disease."


Story Source:

The above story is based on materials provided by Rutgers Cancer Institute of New Jersey. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rajeev K. Boregowda, Oyenike O. Olabisi, Walid Abushahba, Byeong-Seon Jeong, Keneshia K. Haenssen, Wenjin Chen, Marina Chekmareva, Ahmed Lasfar, David J. Foran, James S. Goydos, Karine A. Cohen-Solal. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Letters, 2014; DOI: 10.1016/j.canlet.2014.03.011

Cite This Page:

Rutgers Cancer Institute of New Jersey. "Genetic regulator identified as possible treatment target in melanoma." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403212358.htm>.
Rutgers Cancer Institute of New Jersey. (2014, April 3). Genetic regulator identified as possible treatment target in melanoma. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/04/140403212358.htm
Rutgers Cancer Institute of New Jersey. "Genetic regulator identified as possible treatment target in melanoma." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403212358.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins